CX NEWS
CX Special Session will discuss the use of paclitaxel devices
CX Executive Board Members Gunnar Tepe and Thomas Zeller introduce the CX Special Session which aims to give the last word on paclitaxel and work with the vascular community to find the way forward. [...]
What is new @ CX 2019?
The last word on the paclitaxel controversy The meta-analysis of Katsanos et al in JAHA suggests the need for a reappraisal of paclitaxel-coated balloons and paclitaxel-eluting stents. CX 2019 will carry out an in-depth independent review of [...]
CX 2019: NICE AAA guidelines under the spotlight
The publication of the draft aortic guidelines by the National Institute for Health and Care Excellence (NICE) in May 2018 raised quite a stir. However, the story is not over. In a CX Special [...]
CX 2019: Vascular EDUCATION as it should be
CX is Europe’s largest and longest-running vascular symposium and delivers vascular EDUCATION as it should beCX raises CONTROVERSIES, CHALLENGES the evidence to reach CONSENSUS in a three yearly cycle after discussion involving a world-class faculty and expert audience.CX uses both [...]
CX 2019: The last word on the paclitaxel controversy
Since the publication of Katsanos et al's meta-analysis in the Journal of the American Heart Association (JAHA), the science and support for paclitaxel-releasing devices in the legs is an unfolding story. A CX 2019 [...]
CX 2019 Vascular Access Programme Highlights
Nicholas Inston, member of the CX Vascular Access Executive Board, gives the highlights for this year’s CX Vascular Access Masterclass which will focus on the maintenance and not just the formation of vascular access. [...]